Brief: Heartbeam Provides Update On Regulatory Path Following FDA Decision On 12-Lead ECG Synthesis Software Application
26/11/2025 22:41
Nov 26 (Reuters) - Heartbeam Inc BEAT.O: HEARTBEAM PROVIDES UPDATE ON REGULATORY PATH FOLLOWING FDA DECISION ON 12-LEAD ECG SYNTHESIS SOFTWARE APPLICATION Source text: ID:nBw8fzlZ0a Further company coverage: BEAT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HeartBeam
See all newsBrief: Heartbeam Receives FDA Breakthrough Device Designation For Heart Attack Assessment
Brief: HeartBeam Will Not Build Large Commercial Organization For Arrhythmia Indication
Brief: Heartbeam, Inc. Enters Into At-The-Market Equity Offering Sales Agreement For Up To $25 Million In Common Stock
HeartBeam, Inc. reports results for the quarter ended June 30 - Earnings Summary
HeartBeam Q2 loss per share narrows; co lowers FY net operating cash outflow guidance